Free Trial
NASDAQ:ABVC

ABVC BioPharma (ABVC) Stock Price, News & Analysis

ABVC BioPharma logo
$0.98 +0.07 (+7.19%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.98 0.00 (-0.15%)
As of 04/25/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ABVC BioPharma Stock (NASDAQ:ABVC)

Key Stats

Today's Range
$0.88
$1.01
50-Day Range
$0.58
$1.32
52-Week Range
$0.40
$1.57
Volume
205,087 shs
Average Volume
318,837 shs
Market Capitalization
$15.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

ABVC BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
13th Percentile Overall Score

ABVC MarketRank™: 

ABVC BioPharma scored higher than 13% of companies evaluated by MarketBeat, and ranked 874th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for ABVC BioPharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ABVC BioPharma is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ABVC BioPharma is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ABVC BioPharma has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.56% of the float of ABVC BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ABVC BioPharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ABVC BioPharma has recently decreased by 10.30%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ABVC BioPharma does not currently pay a dividend.

  • Dividend Growth

    ABVC BioPharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.56% of the float of ABVC BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ABVC BioPharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ABVC BioPharma has recently decreased by 10.30%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for ABVC BioPharma this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, ABVC BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.90% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.38% of the stock of ABVC BioPharma is held by institutions.

  • Read more about ABVC BioPharma's insider trading history.
Receive ABVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.

ABVC Stock News Headlines

EQS-News: UPDATE: ABVC BioPharma Announces 2024 Financial Results
Trump’s tariffs just split the AI market in two
Trump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying on cheap foreign hardware—just saw their costs shoot through the roof. For the other group of AI companies, they were just handed a massive competitive advantage. Make no mistake, AI as a whole is still a game-changer for the global economy. But within the AI sector, Trump’s tariffs have created a huge divergence.
ABVC BioPharma Announces 2024 Financial Results
EQS-News: ABVC BioPharma Announces 2024 Financial Results
See More Headlines

ABVC Stock Analysis - Frequently Asked Questions

ABVC BioPharma's stock was trading at $0.59 on January 1st, 2025. Since then, ABVC stock has increased by 65.5% and is now trading at $0.9765.
View the best growth stocks for 2025 here
.

ABVC BioPharma, Inc. (NASDAQ:ABVC) posted its earnings results on Tuesday, April, 15th. The company reported $0.04 earnings per share for the quarter. ABVC BioPharma had a negative net margin of 1,619.65% and a negative trailing twelve-month return on equity of 104.94%.

Shares of ABVC BioPharma reverse split on Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

ABVC BioPharma (ABVC) raised $7 million in an IPO on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share.

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS).

Company Calendar

Last Earnings
4/15/2025
Today
4/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABVC
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,520,000.00
Net Margins
-1,619.65%
Pretax Margin
-1,699.98%

Debt

Sales & Book Value

Annual Sales
$509,589.00
Price / Cash Flow
N/A
Book Value
$1.02 per share
Price / Book
0.93

Miscellaneous

Free Float
11,431,000
Market Cap
$14.91 million
Optionable
Not Optionable
Beta
0.33
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ABVC) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners